This segment focuses on the research, development, manufacturing, and commercialization of Novavax's COVID-19 vaccine, NVX-CoV2373 (Nuvaxovid). The company utilizes its recombinant protein nanoparticle technology, combined with the Matrix-M adjuvant, to generate an immune response against the SARS-CoV-2 virus. Research and development activities include clinical trials to evaluate the vaccine's efficacy and safety, including booster doses and variant-specific formulations. The segment also involves collaborations with partners like Takeda and Sanofi for manufacturing and distribution. Patient impact is significant, as the vaccine provides protection against COVID-19, reducing the severity of illness and hospitalizations. Market positioning is based on providing a protein-based vaccine alternative. Future opportunities include developing combination vaccines and expanding into new markets. Regulatory aspects involve obtaining approvals from various health authorities globally. This segment is crucial for Novavax's revenue generation and its contribution to global health.

This segment is dedicated to the development of NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate. Research and development efforts include Phase 3 clinical trials to assess the vaccine's efficacy and safety in preventing influenza. The company utilizes its proprietary recombinant protein nanoparticle technology and Matrix-M adjuvant to generate a robust immune response against influenza strains. This segment addresses the significant public health need for effective influenza vaccines, aiming to reduce the incidence of influenza-related illnesses and hospitalizations. Market positioning is based on offering an innovative influenza vaccine. Future opportunities include expanding the vaccine's use to broader populations and developing combination vaccines. Regulatory aspects involve obtaining approvals from health authorities. This segment is critical for Novavax's long-term growth and diversification of its product portfolio.

This segment focuses on the development of ResVax, an RSV F protein nanoparticle vaccine candidate, and other RSV vaccine candidates. Research and development activities include Phase II and Phase I clinical trials for different age groups. The company uses its recombinant protein nanoparticle technology and Matrix-M adjuvant to generate an immune response against RSV. This segment addresses the significant unmet medical need for RSV vaccines, particularly for older adults and infants, aiming to reduce the incidence of RSV-related hospitalizations and complications. Market positioning is based on providing an effective RSV vaccine. Future opportunities include expanding the vaccine's use to broader populations and developing combination vaccines. Regulatory aspects involve obtaining approvals from health authorities. This segment is crucial for Novavax's long-term growth and its contribution to global health.